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INTRODUCTION 
 
 Liver cirrhosis is a major yet largely preventable and under-
appreciated cause of global health loss causing more than one million deaths 
in 2010. Variations in cirrhosis mortality at the country level reflect 
difference in the prevalence of risk factors such as alcohol use, Hep. B & C 
infections, NASH. According to WHO, deaths from cirrhosis have been 
estimated to increase and would make it a 12th leading cause of death in 
2020. 
              
 The cardiac complications of cirrhosis have not received the attention 
they  deserve. More than 50 years ago, increased cardiac output in alcohol 
related cirrhosis was attributable to either impaired thiamine utilization or 
the presence of an endogenous vasodilator. Later it became clear that 
cirrhotic cardiac dysfunction is governed by splanchnic vasodilatation. 
Subsequent studies have shown  impaired myocardial contractility and 
electrophysiological abnormalities in cirrhosis, leading to a clinical entity 
called cirrhotic cardiomyopathy. 
 
 Since strict diagnostic criteria for cirrhotic cardiomyopathy are 
lacking and having latent onset of course because of near normal cardiac 
function at rest, the actual prevalence of the disease is unknown. However 
abnormal cardiac responses during exertion, stress, TIPS, liver 
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transplantation are consistent with existence of a cirrhotic cardiomyopathy. 
The mechanisms include impairment of the b-adrenergic receptor signaling, 
abnormal cardiomyocyte membrane lipid deposition and biophysical 
properties, ion channel defects and over activity of humoral 
cardiosuppressant factors. 
 
 World Journal of Gasteroenterology 2015 advances in cirrhosis states, 
“Cirrhotic cardiomyopathy is a chronic cardiac dysfunction characterized by 
impaired contractile response to stress stimuli/impaired diastolic relaxation 
and electrophysiological abnormalities with prolonged QT interval in the 
absence of other known cardiac disease. On the other hand, patients with 
cirrhosis display primary left ventricular dysfunction with normal systolic 
function at rest.” Cirrhotic cardiomyopathy is a subclinical cardiac failure 
and the diastolic dysfunction is assessed by measuring mitral inflow by 
Doppler echocardiography and more modern by Tissue Doppler Imaging 
techniques. 
 
 Hence diastolic dysfunction may serve as an early indicator of 
selecting and appropriately treating the subjects at risk. 
  
Aims and Objectives 
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AIM & OBJECTIVES 
 
 To study the prevalence of cirrhotic cardiomyopathy in 
decompensated liver diseased patients. 
 
 To study the occurrence of diastolic dysfunction in decompensated 
liver diseased patients as an early indicator of cirrhotic 
cardiomyopathy. 
 
Review of Literature 
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REVIEW OF LITERATURE 
 
 In 1761, Gianbattista Morgagni, an anatomic pathologist, first 
identified the cirrhotic transformation of liver in his autopsy specimens. 
 
 In 1826, Laennec coined the term "cirrhosis" - meaning orange color 
in Greek, due to the yellowish-tan color of the cirrhotic liver. 
 
  In 1930, Roessle described pathogenesis of cirrhosis parenchymal 
degeneration, regeneration and scarring. 
 
 Cardiomyopathy is the term derived from the Greek words: ‘Cardia’-
heart, ‘mys’ -muscle, ‘patheia/pathesis’ -disease, which  is a condition 
affecting the heart muscles. The knowledge of cardiac abnormalities in liver 
cirrhosis has not gained importance historically until the existence of a 
hyperdynamic circulatory disorder was described about 60 years ago by 
Kowalski and Murray. These abnormal manifestations such as high cardiac 
output, decreased systemic vascular resistance and widespread arterial 
vasodilatation were initially thought to be due to the direct toxic effect of  
alcohol on the heart, which was primarily described as ‘latent alcoholic 
cardiomyopathy’. 
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 However later on in the 1980’s, studies from further investigations 
and experimental animal models conducted on various stimuli responsible 
for the development of cirrhosis apart from alcohol showed a pattern of 
blunted cardiac contractile responsiveness. These cardiovascular 
abnormalities lead to the evolution of a new entity termed “Cirrhotic 
cardiomyopathy”, which  clinically and pathophysiologically differs from an 
alcoholic cardiomyopathy. 
 
 Let us have an overview of liver cirrhosis and cirrhotic 
cardiomyopathy, their definitions, possible pathogenic mechanisms, clinical 
importance and management along with a brief discussion on the outcome 
of the study based on diastolic dysfunction as an early indicator of cirrhotic 
cardiomyopathy in decompensated liver disease. 
 
CIRRHOSIS OF LIVER:                 
 Cirrhosis of liver is a histopathologically described condition. It 
presents with various clinical features & complications. Cirrhosis is usually 
irreversible. But when the underlying cause is removed, fibrosis can be 
reversed. This can be seen in chronic hepatitis C, hemochromatosis and  
alcohol liver disease. 
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Cirrhosis is defined by three morphological characteristics in the liver  
 Bridging fibrous septa  
 Parenchymal nodules  
 Architectural disruption of the liver 
 
PATHOGENESIS OF CIRRHOSIS:  
Pathogenic processes include  
 Hepatocyte destruction,   
 Extracellular collagen deposition 
 Vascular reorganization 
 
Activation of stellate cells in liver  
 Myofibroblast  
 Transforming growth factor β  
 Deposition of collagen (type I & III) in space of Disse  
 Fibrosis 
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Figure1: Pathogenesis of cirrhosis 
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Figure 2: Cirrhosis of liver – gross pathology 
 
 
 
 
Figure 3: Cirrhosis of liver – Histology 
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CAUSES OF CIRRHOSIS: 
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CLINICAL FEATURES OF CIRRHOSIS:  
 Fatigue  
 Anorexia  
 Weight loss  
 Jaundice  
 Digital Clubbing, hypertrophic osteoarthropathy  
 White nails 
 Palmar erythema  
 Spider naevi 
 Gynaecomatia  
 Hypogonadism – testicular atrophy, loss of libido  
 Parotid enlargement – in alcoholics 
 Dupuytren’s contracture 
 Foetor hepaticus 
 Ascites  
 Peripheral edema  
 Gastrointestinal bleeding  
 Sleep disturbances  
 Altered sensorium  
 Asterixis  
 Splenomegaly 
11 
 
Figure 4: Palmar erythema 
 
 
 
Figure 5: Clinical presentation of cirrhosis 
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LABORATORY FINDINGS IN CIRRHOSIS:  
 Liver enzymes:  
o Moderate elevation of alanine aminotransferase (ALT)  & 
aspartate aminotransferase (AST)   
o Elevated alkaline phosphatase – more common in primary  
biliary cirrhosis & primary sclerosing cholangitis.   
o Elevated Gamma-glutamyl transpeptidase (GGT) – alcohol 
induced  chronic liver disease.   
 Normal Bilirubin in well compensated cirrhosis.  
 Prolonged Prothrombin time  
 Decreased serum Albumin  
 Increased Globulins  
 Reversal of albumin-globulin ratio  
 Hyponatremia – correlates with disease severity  
 
Hematologic  
 Coagulopathy   
 Thrombocytopenia  
 Leukopenia  
 Anemia  
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Ultrasonagraphy of abdomen: 
 Non-invasive test.  
 Small shrunken liver   
 Nodular surface  
 Increased liver echoes.  
 Fibroscan – to assess the severity of liver fibrosis in cirrhosis.   
 Liver biopsy – the confirmatory test, sensitivity 80-100% 
 
PROGNOSTIC SCORES FOR CIRRHOSIS:  
 Child Turcotte Pugh classification (CPC)  
 Model for End stage Liver Disease (MELD) 
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Model for End stage Liver Disease SCORE  
 
  
Ranges between 6 and 40.  
  
 
COMPLICATIONS OF CIRRHOSIS:  
 
Portal hypertension  
Gastro esophageal varices  
Portal hypertensive gastropathy  
Ascites  
Splenomegaly, Hypersplenism  
Spontaneous  bacterial peritonitis  
Hepatorenal syndrome  
Type I  
Type II  
Hepatic encephalopathy  
Hepatopulmonary syndrome  
Portopulmonary syndrome  
Malnutrition   
Coagulopathy   
Factor deficiency  
Fibrinolysis  
Thrombocytopenia  
Bone disease Osteopenia  
Osteomalacia  
Osteoporosis  
Haematological abnormalities  
Anemia  
Neutropenia  
Thrombocytopenia  
Hemolysis   
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PORTAL HYPERTENSION:  
 Hepatic venous pressure gradient (HVPG) > 5 mmHg indicates portal 
hypertension. 
  
It is caused by  
 Increased intrahepatic resistance to blood flow.  
 Increased splanchnic blood flow.  
 
Figure 6: Pathogenesis of Portal hypertension 
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CLASSIFICATION OF PORTAL HYPERTENSION:  
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Clinical features:  
 Upper gastrointestinal bleeding due to varices,   
 Ascites & peripheral edema  
 Splenomegaly  
 Reduced platelets and leukocytes.   
  
Treatment:  
Aimed at  
 Reducing portal blood flow  
 Decreasing intrahepatic resistance  
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 Drugs decreasing Portal venous blood flow   
 Nonselective β-blockers – propranolol, nadolol  
 Vasopressin  
 Somatostatin & octreotide  
 Drugs reducing Intrahepatic Resistance:      
 α1-Adrenergic blockers – prazosin  
 Angiotensin receptor blockers (ARBs) – losartan  
 Nitrates  
 Endoscopic therapy for varices 
 Shunt procedures – TIPS  
 
Figure 7: Anatomy of portal circulation 
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VARICEAL HEMORRHAGE:  
 Bleeding from varices occurs due to increased portal pressure. It is 
dreadful complication.   
 Increased portal pressure portosystemic collaterals dilate varices, 
walls become thinner.   
 Any further increase in variceal pressure / size rupture & clinical 
hemorrhage  
 Gastroesophageal varices – most common source of upper 
gastrointestinal bleed in cirrhotic patients.   
 Incidence 5–15% / per year. 
 
 Bleeding from varices occurs in one third of cirrhotics Caput medusa 
– prominent veins radiating from umblicus Sites of portal-systemic 
anastomosis in cirrhosis:  
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Figure 8: Sites of portal-systemic anastomosis in cirrhosis 
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Endoscopy  
Varices are identified by endoscopy.  
Upper GI endoscopy  gastroesophageal varices   
Sigmoidoscopy rectal varices  
Varices are graded by endoscopy in to 3 types  
 Grade I  
 Grade II  
 Grade III  
 
Figure 9: Endoscopic Grading of varices 
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Figure 10: Upper GI endoscopy showing esophageal varices 
 
 
 
Portal hypertensive gastropathy – in fundus of stomach, mosaic-like pattern  
 
Factors predicting the risk of bleeding: 
 Severity of cirrhosis (Child's class, MELD score)  
 Height of hepatic vein wedge vein pressure  
 Location & size of varices  
 Endoscopic findings – cherry red spots, red wale signs, erythema   
  
Treatment of variceal hemorrhage due to portal hypertension include 
 Acute variceal hemorrhage – resuscitation, vasoconstricting agents 
like somatostatin or octreotide, emergency endoscopic sclerotherapy 
or band ligation. 
 Primary prophylaxis – non selective beta blockers or endoscopic 
variceal band ligation.  
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 Prevention of re-bleeding after an initial variceal bleed – beta 
blockade, portosystemic shunt surgery (TIPS)   
  
ASCITES:  
 Ascites - accumulation of free fluid in the peritoneal cavity.  
 Portal hypertension is the common cause for ascites.   
 Malignant or infectious causes can be present as well.  
 
Pathogenesis: 
 Increase in portal pressure & vasodilation of the splanchnic arterial 
system. Increase in portal venous inflow & increased production of 
splanchnic lymph. Vasodilating factors (nitric oxide) are responsible for 
vasodilatory effects.  
 
 Activation of renin-angiotensin-aldosterone system and 
hyperaldosteronism leads to retention of sodium causing fluid accumulation 
& expansion of ECF volume.  
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This results in peripheral edema and ascites; 
 
 
 Hypoalbuminemia (due to reduced synthesis from liver) & reduced 
plasma oncotic pressure fluid loss from vascular compartment into 
peritoneal cavity.  
 
 Ascites develops insidiously. Patients usually have 1-2 litres of fluid 
in the abdomen before they are aware that there is an increase.   
 
 Massive ascites compromise respiratory function, dyspnoea occurs.   
 
 Hepatic hydrothorax also contributes to respiratory symptoms.  It is 
common on right side. Free flow of fluid into the thoracic cavity occurs 
through a diaphragmatic rent.  
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SBP – SPONTANEOUS BACTERIAL PERITONITIS  
 Spontaneous infection of ascitic fluid without intra-abdominal source.   
 Occur in up to 30% of individuals  
 25% in-hospitality mortality rate.   
 Most common organisms – Escherichia coli & other gut bacteria.   
 Diagnosis criteria - ascitic fluid absolute neutrophil count >250 
cells/µL.  
 
HEPATORENAL SYNDROME (HRS):  
 Functional renal failure with no obvious renal pathology.   
 Incidence 10% in advanced cirrhosis / acute liver failure.   
 Type I HRS – progressive impairment in kidney function with 
significant reduction in creatinine clearance within 1-2 weeks.   
 Type II HRS – reduction in GFR with an elevation of serum 
creatinine level, but it is fairly stable, better outcome than type I HRS. 
` 
HEPATIC ENCHEPHALOPATHY:  
 Hepatic encephalopathy (HE) – transient & reversible neurologic & 
psychiatric manifestations in the setting of hepatic failure. 
 Occurs in 50-70% of cirrhotics  
 Poor prognostic indicator   
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 Without liver transplantation in HE – survival rates 42% & 23% 
respectively in 1st and 3rd year  
 Symptoms - mild mental disturbances to coma.   
 Triggered by a precipitating event resulting in raised level of 
ammonia.   
 Precipitating events  
 Infections  
 Increased protein load  
 Gastrointestinal bleeding  
 Electrolyte disturbances - hypokalemia  
 Intra & extrahepatic shunting of portal blood into systemic circulation 
toxic substances not detoxified by liver metabolic abnormalities in the 
central nervous system. 
 
Treatment:   
 Avoiding precipitating events  
 Reduction of elevated serum ammonia production  
 Disaccharides (non absorbable) – lactulose  
 L-ornithine L-aspartate, Zinc, Flumazenil  
 Transplantation of liver 
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COAGULOPATHY:  
 Coagulopathy common in cirrhotic patients.   
 Decreased clotting factor synthesis.   
 Impaired clearance of anticoagulants.   
 Hypersplenism due to portal hypertension causing thrombocytopenia. 
 
PULMONARY MANIFESTATIONS IN CIRRHOSIS  
 Pulmonary complications of Cirrhosis can affect the lung 
parenchyma, pulmonary circulation and the pleura. Pulmonary 
manifestations in cirrhosis can present as follows,   
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 Hepato-pulmonary syndrome (HPS)  
 Hepatic hydrothorax  
 Porto-pulmonary hypertension (PPH)   
 The most common clinical features are Dyspnea and hypoxemia. 
 
HEPATOPULMONARY SYNDROME:  
 Hepatopulmonary Syndrome (HPS) is characterized by 
 Liver disease  
 Hypoxemia    
 Pulmonary microvascular dilatation  
 
 Liver-lung relationship was first noted in 1884 by Fluckiger. But this 
was not formalized at that time. In 1997 Kennedy & Knudson explained 
HPS as a disease presenting with hypoxemia and intrapulmonary vascular  
dilatations. 
  
 About 4% to 19% prevalence rate of HPS. Most cases have occurred 
in patients with cirrhosis & portal hypertension. Due to different cut-off 
values (in various studies) for defining arterial hypoxemia there is disparity 
in the prevalence rate of HPS. 
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PATHOPHYSIOLOGY: 
 
CLINICAL FEATURES:  
 The clinical course of HPS is poorly defined. Acute development 
(days to weeks) of the syndrome appears unlikely. High suspicion is needed 
to diagnosis HPS. Clinical features of HPS include   
 Dyspnoea – insidious onset, most common feature 
 Platypnoea  
 Orthodeoxia   
 Cyanosis  
 Digital Clubbing  
 Spider angioma 
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MANAGEMENT OF HPS:  
Medical treatment:  
 Following drugs were tried in HPS  
 Garlic preparations  
 Pentoxifylline – TNF alpha inhibitor  
 Methylene blue & inhaled N (G)-nitro-L-arginine methyl ester– direct 
inhibition of nitric oxide   
 Somatostatin  
 Indomethacin 
 Steroids  
 N-acetylcysteine    
 Almitrine bimesylate 
 Oxygen therapy  
 Iloprost 
 Intervention Radiological therapy 
 Transjugular intrahepatic portosystemic shunt (TIPS) – control portal 
pressure  
 Embolotherapy with Yttrium-90 glass microspheres  – eliminate 
intrapulmonary shunts  
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Liver transplantation: 
 Only proven treatment for HPS.   
 After liver transplantation complete resolution of hypoxemia occurs 
in 85% of patients. 
 In some patients resolution may take more time (more than a year).  
 Mortality after liver transplantation is significantly high with 1-year 
survival rate – 71%. 
 Severe degree of hypoxemia & prominent intrapulmonary shunting 
associated with increased mortality rate. 
 
Complications after OLT:   
 Pulmonary arterial hypertension 
 Cerebral embolic hemorrhage  
 Post-operative hypoxemia requiring prolonged  ventilation  
 
Indication for orthotopic liver transplantation in HPS: 
 If PaO2  50 – 60 mmHg    
 If PaO2  <50 mmHg (on an individual basis)  
 Liver transplantation is the ideal treatment for HPS as there are no 
proven medical therapy. 
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HEPATIC HYDROTHORAX   
 Presence of pleural effusion without intrinsic respiratory or cardiac 
pathology in patients with cirrhosis.   
 Incidence up to 10%  
 Movement of free fluid from peritoneal cavity in to pleural cavity 
through small diaphragmatic rents.  
 Can occur even without ascites.   
 Most common on right side (67%)  
 May be bilateral (17%) or left sided 17%  Spontaneous bacterial 
empyema can occur  
Treatment: 
 To decrease ascitic fluid formation  
 Therapeutic aspiration (to relieve dyspnea)   
 To obliterate the rent between pleura & peritoneum  
 Shunt surgery (TIPS)  
 Pleurodesis 
 
PORTOPULMONARY HYPERTENSION: (PPH)  
Portopulmonary hypertension (PPH) is characterized by 
 Elevated mean pulmonary pressure (>25 mmHg at rest, >30mm Hg 
with exercise. 
 Increased pulmonary vascular resistance (>240 dynes s/cm) 
 Pulmonary artery occlusion pressure (<15 mmHg) 
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Severity of PPH: 
Severity Mean arterial pulmonary pressure 
Mild 25 – 35 mm Hg 
Moderate 35 – 50 mm Hg 
Severe >50 mm Hg 
 
Incidence of PPH in cirrhosis - 6%  
 
PATHOGENESIS: 
Pathogenesis of PPH is not well understood 
 Embolic factors:   
 Embolic material via portosystemic shunts enter lungs  
Plexogenic factors: 
 Bypassed vasoactive substances  
 Produce plexogenic arteriopathy  
 Increased pulmonary blood flow & proliferation of smooth muscle 
endothelial damage and vascular remodeling  
 Risk of developing pulmonary hypertension – increases with duration 
of portal hypertension  
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Figure 19: Histology of lung in portopulmonary hypertension 
 
Intimal and medial thickening of pulmonary artery (straight arrow) 
Channel like structures forming plexiform lesions (curved arrow) 
 
CLINICAL FEATURES   
 Asymptomatic in most patients  
 Exertional dyspnea → dyspnea at rest  
 Fatigue   
 Syncope  
 Chest pain  
 Elevated JVP  
 Loud pulmonary component (P2) of  2nd heart sound  
 Systolic murmur  
 Severe pulmonary hypertension 
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DIAGNOSIS   
Electrocardiogram  
 Right atrial enlargement  
 Right ventricular hypertrophy   
 Right bundle branch pattern.  
Chest X-Ray  
 Pulmonary arteries – prominent   
 Cardiomegaly  
 
Computed Tomography 
 Evidence of pulmonary hypertension – main pulmonary artery 
diameter ≥ 29 mm  
Echocardiogram  
 Noninvasive screening test  
 Elevated right ventricular systolic pressure (RVSP)  
 Tricuspid regurgitant jet → Pulmonary hypertension  
Right heart catheterization 
 Confirmation of PPH   
 Measures pulmonary artery pressure  
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PROGNOSIS:  
 Mean survival – 15 months  
 High perioperative mortality 
 Screening for portopulmonay hypertension – mandatory in patients 
awaiting liver transplantation 
 
TREATMENT OF PORTOPULMONARY HYPERTENSION:   
Pharmacological Therapy : 
 Vasodilators - mainstay of therapy, reverses the vasoconstriction    
 Prostacyclin – epoprostenol, iloprost – vasodilator & platelet  
aggregation  inhibitor   
 Endothelin receptor antagonists – Bosentan, Ambrisentan    
 Inhaled  Nitric Oxide  
 Phosphodiesterase  inhibitors 
 L-arginine   
 Diuretics  
 
Liver transplantation:  
 Role of OLT (orthotopic liver transplantation) – controversial  
 Not the curative treatment in PPH  
 Contraindicated in patients with mean PAP > 50 mm Hg  
 Liver Transplantation – indicated in selected patients after clinical 
improvement by medical therapy  
 Medical therapy – used to bridge PPH patients to OLT 
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CARDIOVASCULAR CHANGES IN CIRRHOSIS:  
 Hyperdynamic circulation occurs in cirrhosis.   
 Decreased peripheral vascular resistance, decreased arterial BP and 
increased cardiac output.   
 Kowalski et al were the first to report that cirrhotic patients had 
abnormal cardiovascular changes and a prolonged QTc. 
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Hemodynamic changes in different vascular territories in patients with 
cirrhosis at rest. 
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CIRRHOTIC CARDIOMYOPATHY 
 Cirrhotic cardiomyopathy is generally a subclinical entity, which 
tends to manifest under conditions of stress. Since a definite diagnostic 
criteria is lacking, the exact prevalence of the disease remains unknown, as 
also patients with compensated cirrhosis do  not exhibit signs or symptoms 
of the disease at early stages. However, electrophysiological abnormalities 
and echocardiographic imaging modalities are the best available screening 
tests to diagnose this syndrome. 
 
Cirrhotic cardiomyopathy is characterized by   
Systolic dysfunction  
 Resting ejection fraction <55% 
 With exercise, volume change or pharmacological stress blunted 
increase in cardiac output.                                                                    
 
Diastolic dysfunction  
 E/A ratio < 1.0 
 Prolonged isovolumetric relaxation time & deceleration time  
 
Electrophysiological changes  
 Diagnostic and supportive criteria for cirrhotic cardiomyopathy based 
upon 2005 World Congress of Gastroenterology. 
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Mechanism of Cirrhotic cardiomyopathy 
 
 
 Potential pathophysiological components implicated in the 
development of Cirrhotic cardiomyopathy 
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PATHOPHYSIOLOGY OF CIRRHOTIC CARDIOMYOPATHY 
 Several factors have been implicated in the pathogenesis of cardiac 
dysfunction in cirrhosis which includes primarily activation of renin-
angiotensin aldosterone system(RAAS) and sympathetic nervous 
system(SNS) leading to autonomic dysfunction. Accumulation of 
endogenous cardiodepressant factors like carbon monoxide, nitric oxide and 
cannabinoids. Alterations in lipid metabolism alter the cell plasma 
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membrane physical properties by increasing the cholesterol content along 
with changes in the membrane fluidity, all of which play an  important role 
in the β-adrenergic receptor dysregulation. Other factors like inflammation 
in the setting of intestinal bacterial overgrowth, altered gut permeability and 
bacterial translocation which release inflammatory mediators such as 
cytokines, reactive oxygen and nitrogen species. 
 
CARDIOVASCULAR AUTONOMIC DYSFUNCTION 
(β-adrenergic receptor dysfunction) 
 The β-adrenergic receptors (βAR) system plays a crucial role in 
modulating the contractility of cardiac muscle cells. Activation of βAR by 
epinephrine and norepinephrine couples with Gs­protein and leads to the 
stimulation a membrane­bound adenylate cyclase and the subsequent release 
of cAMP. The Gs protein also promotes the direct activation of the calcium 
channel of the sarcolemma. The second messenger, cAMP, activates a 
cAMP­ dependent protein kinase A (PKA)  which  phosphorylates several 
intracellular proteins such as L­type calcium channels, phospholamban, 
troponinⅠ,ryanodine receptors thus leading to Ca2+ entering the cell. The 
cytosolic­free Ca2+ binds to the protein troponin C and interacts with 
tropomyosin between the actin and myosin filaments which allows the 
contraction of the myofibrils to take place (cardiac systole). 
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 Cardiac dysfunction in patients with cirrhosis occurs in the setting of 
a circulatory dysfunction characterized by a marked splanchnic arterial 
vasodilation. At the initial stages of cirrhosis, the circulatory dysfunction is 
compensated by the development of a hyperdynamic circulation. But later 
on during the course of the disease, the progression of liver disease and 
portal hypertension results in progressive vasodilatation, leading to 
reduction in the effective arterial blood volume which in turn activates the 
RAAS and the SNS by baroreceptor-mediated stimulation. These circulatory 
changes can lead to the cardiac dilatation of the left chambers and the 
development of functional changes in the heart leading to blunted 
baroreceptor responsiveness and heart rate variability. Enhanced 
sympathetic tone with increased exposure to norepinephrine for longer 
periods are known to cause myocardial injury and impairment of 
β­adrenergic receptor function. 
 
 Cardiomyocytes of cirrhotic animals showed reduced contractility via 
impairment of the βAR signalling (down-regulation, desensitization) which 
in turn leads to a reduction in βAR density, Gs proteins, and AC activity 
with resultant decreased cAMP generation. Hence postreceptor signaling 
through cAMP is severely impaired. 
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CARDIOMYOCYTE PLASMA MEMBRANE CHANGES         
 Cirrhotic patients as well as experimental animal models were found 
to have changes in membrane fluidity which is attributed to increase in 
plasma membrane cholesterol content and cholesterol-to-phospholipid 
molar ratio as shown in a study of bile duct-ligated cirrhotic rat model. The 
decreased fluidity of cardiomyocyte membrane interferes with the function 
of βAR, L-type calcium and potassium channels and impair stimulation of 
M2 muscarinic receptor which inhibits adenylyl cyclase, M1 and M3 
muscarinic acetylcholine receptors linked to intracellular signaling pathways 
in stimulating phospholipase C, that modulate pacemaker activity, 
atrioventricular conduction and force of contraction. Such alterations in 
membrane properties are responsible for the ECG abnormalities in cirrhotic 
patients. 
 
HUMORAL CARDIODEPRESSANT MOLECULAR MEDIATORS 
 Endocannabinoids (ECS) are the lipid signaling molecules that form 
the endogenous ligands for cannabinoid receptors. The ECS system includes 
arachidonoyl ethanolamine(AEA) and 2-arachidonoylglycerol(2-AG) which 
are elevated in cirrhosis. The activation of CB1  receptors decreases cAMP 
and inhibits L-type calcium channels resulting in decreased influx of 
calcium into the cytosol thus causing impairment of the cardiac contraction. 
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 Carbon monoxide(CO) is an endogenously produced short-lived gas 
via haem metabolism, whose degradation is catalyzed by haem 
oxygenase(HO). In cirrhosis, there is upregulation of HO activity and 
enhanced CO production through activation of the SNS, increased levels of 
norepinephrine or increased cytokines from the enhanced portal venous 
bacteremia and endotoxemia.CO favours splanchnic arterial vasodilation 
and decrease ventricular contractility through increased cyclic guanosine 
monophosphate(cGMP) and depressed calcium influx. 
 
 Nitric oxide (NO) is produced in cardiac myocytes from either 
constitutive (NOS) or inducible (iNOS) forms. NOS produced from 
neuronal and endothelial NOS has cardioprotective effects by inhibtion of 
apoptosis whereas inducible NOS produced from inflammatory mediators 
cardiotoxic effects through suppression of cardiac muscle contractility and 
induction of apoptosis. Experimental cirrhotic rat models expressed high 
levels of iNOS messenger ribonucleic acid as well as soluble cyclic GMP 
which blocks L-type calcium channels thus impairing the responsiveness of 
pacemaker cells to adrenergic stimuli. The role of NOS in impairing the 
papillary muscle contractility was further revealed by the administration of  
non-specific NOS inhibitor L-NMMA( N omega monomethyl-L-arginine) 
which significantly improved the ventricular contractile function.                                                           
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Pathogenic mechanism of cardiomyocyte contraction in cirrhosis 
 
+: stimulatory influence; -: inhibitory influence. βAR: β-adrenergic 
receptors; CB1: Cannabinoid 1-receptor; AC: Adenylcyclase; cAMP: Cyclic 
adenosine monophosphate; Gαi: Inhibitory G protein; Gαs: Stimulatory G 
protein; RGS: Regulator of G-protein signaling; PLN: Phosphoslamban; 
PKA: Protein kinase A; cGMP: Cyclic guanosine monophosphate; PDE: 
Phosphosdiesterase; RyR: Ryanodine receptor; HO: Haemoxygenase; CO: 
Carbon monoxide; NO: Nitric oxide; NOS: Nitric oxide synthase; TNFα: 
Tumour necrosis factor α. 
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 The activation of CB1 inhibiting L-type calcium channels and AC 
together with increased NO and CO levels via a cGMP-dependent 
mechanism also contribute to decreased calcium ion influx or release from 
the sarcoplasmic reticulum with a related fall of calcium ion content and 
cardiac muscle contractility. 
 
ELECTROPHYSIOLOGICAL ABNORMALITIES 
           Several electrophysiological changes are found in cirrhotic patients 
as QT interval prolongation, electromechanical dyssynchrony, chronotropic 
& ionotropic incompetence. All these manifestations are explained due to 
autonomic dysfunction (impaired response to SNS / vagus stimulation), 
exposure to humoral factors (cytokines, endotoxins, bile salts) through 
porto-systemic shunts. 
 
QTc interval prolongation 
         QT interval represents the depolarization and repolarization of 
ventricles. Normal QT interval is less than 0.44s. It is said to be prolonged 
when it is greater than 0.44s in men and 0.46s in women. This prolongation 
is due to decreased function of two types of K+ channels and 
sympathoadrenergic hyperactivity. Since QT interval is affected by heart 
rate, rate corrected (QTc) interval should be calculated. TIPS / GI bleed 
tends to prolong the QT interval. Patients with prolonged QT interval are at 
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increased risk of developing ventricular arrhythmias. QT interval gets 
corrected in 50% subjects after liver transplantation. 
 
 
 
Electro-mechanical dyssynchrony 
 Electro-mechanical systole represents the duration of total systolic 
time interval and has two major components: pre-ejection and LV ejection 
phases. Normally, the time interval between the onset of electrical and 
mechanical systole is well maintained whereas electrical systole was longer 
than mechanical systole in cirrhotic patients with QTc prolongation. An 
impaired response to adrenergic drive due to decreased density of L-type 
calcium channels have been shown to affect the excitation contraction 
coupling. All these disturbances lead to defective K+ channel function in 
ventricular myocytes causing electro-mechanical dyssynchrony especially in 
the setting of variceal hemorrhage and blood transfusion. 
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Chronotropic & Ionotropic Incompetence   
 In cirrhotic patients after development of ascites, there was overt 
evidence of contractile dysfunction despite decrease in both afterload 
(arterial vasodilatation) and preload (venous return). Reduction in cardiac 
index and increase in SVR together has contributed to pump dysfunction. 
HR / plasma NA ratio was significantly reduced in patients with grade II 
LVDD when compared to those without LVDD. The hearts of cirrhotic 
patients show blunted ability to increase heart rate and LVEF after 
appropriate stimulation with exercise, drug infusion, or postural challenge. 
 
CARDIAC DYSFUNCTION ABNORMALITIES 
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Diastolic Dysfunction        
        
                      
 LVDD  serves  an early indicator of cirrhotic cardiomyopathy as 
evidenced by the presence of  diastolic dysfunction in 40-50% patients with 
liver cirrhosis. Cardiac muscle hypertrophy was demonstrated in 75% 
patients with LVDD and cirrhosis. The underlying mechanisms include  
defects in passive tension of myofilament patterns as well as impaired 
myocardial relaxation / due to abnormalities in calcium exchange through 
the sarcoplasmic reticulum. 
 
 Development of fibrosis by aldosterone mediated stimulation of 
fibroblast proliferation, collagen synthesis and release of pro-inflammatory 
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factors leading to activation of matrix metalloproteinases and 
overexpression of TGF-β. 
 
 Due to diastolic dysfunction, increased blood volume in left atrium 
(LA) augment the transmitral pressure gradient. So diagnostic evidence of 
diastolic dysfunction can be obtained both invasively by means of Left 
Ventricular End-Diastolic Pressure > 16mmHg / PCWP > 12mmHg and 
non-invasively by echocardiography. Cirrhotic hearts show the following 
features increased  LA size and volume. 
 
 Increased thickness of posterior wall of left ventricle and 
interventricular septum contributing increased LV diameter without volume 
changes. Prolongation of IVRT (Isovolumetric Relaxation Time) and 
deceleration time (DT) of E wave. Decreased peak E velocity (early rapid 
filling phase) and increased peak A velocity (atrial contraction during late 
diastole). E/A ratio is reduced. 
 
 E/A ratio measured by conventional echocardiography has several 
limitations as it is dependent on age and preload status. Tissue Doppler 
Imaging (TDI) overcomes these factors as it measures the velocity of 
myocardial displacement at basal & septal corner of annulus mitral (e’) as 
LV expands in diastole, independent of volume status and LA pressure. 
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 The American Society Echocardiography (ASE) defines LVDD by 
the presence of septal e’ < 8cm/s, lateral e’ < 10cm/s, mitral inflow patterns 
and LA volume index (LAVI) ≥ 34 mL/m2. Hence LVDD is more 
accurately detected by Tissue Doppler Imaging studies. 
 
Systolic Dysfunction 
 Systolic dysfunction is mostly latent in patients with Cirrhotic 
cardiomyopathy. Most patients have normal systolic function at rest and the 
impaired ventricular function is manifested by subjecting the patients to 
stress challenge. These include pharmacological infusion / exercise / 
postural challenges. Measurement of systolic time interval also helps to 
evaluate the ventricular dysfunction. The pre-ejection period / left 
ventricular ejection time ratio has been seen to increase from baseline after 
exercise in cirrhotic patients. 
 
 Though systolic dysfunction is more common with alcoholic heart 
muscle disease, it is also present in non-alcoholic cirrhotic patients. Studies 
revealed that systolic dysfunction may be influenced by pre-load, after-load 
and diastolic dysfunction but reduced myocardial reserve and impaired 
oxygen extraction (due to imbalanced NO production and function) are the 
main factors. 
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TREATMENT 
 The treatment of cirrhotic cardiomyopathy is non-specific and 
directed towards patients with symptoms of heart failure. 
 
Pharmacologic therapy 
 Pharmacological treatment includes beta blockers, calcium channel 
blockers, ACE inhibitors, AT II receptor blockers which retard the 
progression of grade I LVDD. The role of beta-blocker is controversial and 
need further studies. Cardiac glycosides are not beneficial. Patients with 
heart failure should be treated with salt & fluid restriction, diuretics and 
aldosterone antagonists. Diuretics cause decrease in LV pre-load while 
aldosterone antagonists can reduce the LV wall thickness. 
 
Liver transplantation 
 Liver transplantation is the gold standard treatment of cirrhotic 
cardiomyopathy. However if not safely performed, it carries the risk of 
developing cardiovascular complications in about 25% patients during post-
operative period. Studies show that QT interval normalizes within 3 months 
and cardiac function within 6-12 months after liver transplantation and 
hence reverses cirrhotic cardiomyopathy. 
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PROGNOSIS 
 Cirrhotic cardiomyopathy is a subclinical entity. The disease becomes 
manifested under acute stress conditions like bleeding/ infection / surgery / 
pharmacological infusion leading to worsening of decompensation. Survival 
rate depends on severity of LVDD where impaired cardiac condition, as 
inability of increasing cardiac output in response to stress, contributes to 
unfavourable outcomes.  
 
 Eventhough liver transplantation reverses cirrhotic cardiomyopathy, 
patients with grade II LVDD carry poorer long term survival outcome rates 
during immediate post-operative period. Since severity of diastolic 
dysfunction significantly depends on severity of liver disease, patients 
belonging to child pugh class B and C should be subjected to basic 
echocardiographic evaluation to identify and manage the patients at risk. 
  
Materials and Methods 
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MATERIALS AND METHODS 
 
SOURCE OF DATA:  
 Patients admitted in Institute of Internal Medicine, Madras Medical 
College and Rajiv Gandhi Government General Hospital, Chennai-3 
diagnosed to have Cirrhosis of liver, fulfilling the inclusion and exclusion 
criteria were included in the study group. 60 such patients were taken up for 
this study.  
  
STUDY DESIGN:   
 A hospital based observational prospective study.  
 
STUDY DURATION:   
 This study was done over a period of six months. 
  
INCLUSION CRITERIA: 
 Patients with decompensated liver disease admitted in medical wards. 
 
EXCLUSION CRITERIA:  
 Patients with other cardiovascular ailments as coronary artery disease, 
rheumatic heart disease, congenital heart disease. 
 
 Patients with diabetes mellitus 
 Patients with hypertension 
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 Patients with hypo/hyperthyroidism / other endocrine disorders. 
 Patients with severe anemia 
 Patients with terminal  illness. 
 
DATA COLLECTION AND METHODS:  
 Data was collected in a pretested proforma from eligible patients. 60 
patients were selected on the basis of simple random sampling. They were 
subjected to detailed history taking and clinical examination. Severity of the 
cirrhosis was evaluated by Child-Pugh criteria and divided in three groups: 
A(mild), B(moderate), and C(severe). 
 
The following investigations were done.  
Liver function tests - Total bilirubin 
                                   Direct/Indirect bilirubin 
                                   SGOT/SGPT 
                                   Serum total protein/albumin 
                                   Albumin : Globulin ratio 
     PT-INR,aPTT 
     BT/CT 
Complete hemogram 
Renal function tests&serum electrolytes 
Viral markers 
USG Abdomen & Pelvis 
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Portal venous Doppler study 
12-lead ECG  
ECHOCARDIOGRAPHY 
12-LEAD ECG: 
 A 12-leadsurface EGG was obtained from all subjects in the supine 
position immediately before echocardiography by using  machine. The ECG 
was recorded at  a paper speed of 25mm/s and studied for the presence of 
prolonged QT interval (rate corrected). 
 
ECHOCARDIOGRAPHY: 
 A Conventional 2D Echocardiography was performed to evaluate the 
diastolic dysfunction by the following indices: left ventricular filling derived 
from mitral valve diastolic flow velocity curve, such as 
 E/A ratio, where E is the early diastolic annular velocity (mitral 
inflow velocity) and A is the late filling wave(velocity caused by 
atrial contraction) 
 DT, the atrial deceleration time. 
 E/Ea ratio, Ea is the peak early diastolic annular velocity.   
 Severity grading of Diastolic Dysfunction 
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STASTICAL METHODS APPLIED:  
 SPSS software was used for data analysis. Statistical significance was 
indicated by the Chi-square test. Variables were considered to be significant 
if p <0.05. 
  
Observation and Results 
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OBSERVATION AND RESULTS 
 
Table 1. CORRELATION BETWEEN AGE AND DIASTOLIC 
DYSFUNCTION IN DCLD 
Pearson Chi-Square=2.004  p=0.572 
 
 Diastolic dysfunction has no significant correlation with age distribution. 
 
Table 2. CORRELATION BETWEEN SEX AND DIASTOLIC 
DYSFUNCTION IN DCLD 
Pearson Chi-Square=0.167 p=0.683 
 
 Diastolic dysfunction has no significant correlation with  sex predilection. 
  
Crosstab 
Age Group 
LVDD 
Total 
NO LVDD 
30-40Years 
Count 5 1 6 
% 13.9% 4.2% 10.0% 
41-50 years 
Count 16 14 30 
% 44.4% 58.3% 50.0% 
51-60 years 
Count 13 8 21 
% 36.1% 33.3% 35.0% 
Above 60 Years 
Count 2 1 3 
% 5.6% 4.2% 5.0% 
Total 
Count 36 24 60 
% 100.0% 100.0% 100.0% 
Crosstab 
Sex LVDD Total 
NO LVDD 
Male Count 30 19 49 
% 83.3% 79.2% 81.7% 
Female Count 6 5 11 % 16.7% 20.8% 18.3% 
Total Count 36 24 60 
% 100.0% 100.0% 100.0% 
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Table3. CORRELATION BETWEEN CAUSATIVE FACTORS AND 
DIASTOLIC DYSFUNCTION IN DCLD 
a) ALCOHOL AND LVDD 
Crosstab 
ALCOHOL LVDD Total 
NO LVDD 
- 
Count 9 6 15 
% within LVDD 25.0% 25.0% 25.0% 
+ 
Count 27 18 45 
% within LVDD 75.0% 75.0% 75.0% 
Total 
Count 36 24 60 
% within LVDD 100.0% 100.0% 100.0% 
 
Pearson Chi-Square=0.0 p=1.00 
 
 
b) VIRAL CAUSE AND LVDD 
Crosstab 
VIRAL 
LVDD 
Total 
NO LVDD 
- 
Count 33 21 54 
% within LVDD 91.7% 87.5% 90.0% 
HBV 
Count 1 3 4 
% within LVDD 2.8% 12.5% 6.7% 
HCV 
Count 2 0 2 
% within LVDD 5.6% 0.0% 3.3% 
Total 
Count 36 24 60 
% within LVDD 100.0% 100.0% 100.0% 
 
Pearson Chi-Square=3.403  p=0.182 
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c).  OTHER CAUSES AND LVDD 
Crosstab 
OTHERS LVDD Total 
NO LVDD 
- 
Count 30 20 50 
% within LVDD 83.3% 83.3% 83.3% 
+ 
Count 6 4 10 
% within LVDD 16.7% 16.7% 16.7% 
Total 
Count 36 24 60 
% within LVDD 100.0% 100.0% 100.0% 
 
Pearson Chi-Square=0.0 p=1.00 
 
 
 Diastolic dysfunction has no significant correlation with causative factors. 
 
  
  
63 
 
Table 4. CORRELATION OF SEVERITY GRADING BETWEEN 
HEPATIC ENCEPHALOPATHY AND DIASTOLIC DYSFUNCTION IN 
DCLD 
 
Crosstab 
HEPATIC ENCEPHALOPATHY LVDD Total NO LVDD 
- Count 35 15 50 % within LVDD 97.2% 62.5% 83.3% 
Gr1 Count 1 6 7 % within LVDD 2.8% 25.0% 11.7% 
Gr2 Count 0 3 3 % within LVDD 0.0% 12.5% 5.0% 
Total Count 36 24 60 % within LVDD 100.0% 100.0% 100.0% 
Pearson Chi-Square=12.679*   p=0.002 
 
 
 
 
 Severity of diastolic dysfunction has highly significant (p-value 0.002) 
correlation with increasing grading of hepatic encephalopathy. 
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Table 5. CORRELATION BETWEEN INCREASING SERUM BILIRUBIN 
LEVELS AND DIASTOLIC DYSFUNCTION GRADING IN CIRRHOTIC 
CARDIOMYOPATHY 
 
Crosstab 
ECHOCARDIOGRAPHY 
NORMAL LVSF 
BILLRUBIN 
Total 
<2 2.1-4 4.1-10 ABOVE10 
Gr.1 LVDD 
Count 2 6 4 3 15 
% 13.3% 40.0% 26.7% 20.0% 100.0% 
Gr.2 LVDD 
Count 0 0 3 5 8 
% 0.0% 0.0% 37.5% 62.5% 100.0% 
Total 
Count 2 6 7 8 23 
% 8.7% 26.1% 30.4% 34.8% 100.0% 
Pearson Chi-Square=9.574* P=0.023 
 
 
 
 
  
 Severity of diastolic dysfunction has significant (p-value 0.023) 
correlation with increasing serum bilirubin levels. 
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Table 6. CORRELATION BETWEEN SEVERITY OF LIVER DISEASE 
(BY CHILD PUGH SCORING SYSTEM) AND DIASTOLIC 
DYSFUNCTION GRADING IN CIRRHOTIC CARDIOMYOPATHY 
 
Crosstab 
ECHOCARDIOGRAPHY 
NORMAL LVSF 
CHILD PUGH SCORING 
SYSTEM Total 
B C 
Gr.1 LVDD 
Count 13 2 15 
% 86.7% 13.3% 100.0% 
Gr.2 LVDD 
Count 0 8 8 
% 0.0% 100.0% 100.0% 
Total 
Count 13 10 23 
% 56.5% 43.5% 100.0% 
Pearson Chi-Square=15.947** P<0.001 
 
 
 
 
 
 Severity of diastolic dysfunction has highly significant (p-value <0.001) 
correlation with increasing  severity  of liver disease (by child-pugh scoring 
system).  
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Frequency Table 
 
Table 7. AGE 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 
30-40Years 6 10.0 10.0 10.0 
41-50 years 30 50.0 50.0 60.0 
51-60 years 21 35.0 35.0 95.0 
Above 60 
Years 3 5.0 5.0 100.0 
Total 60 100.0 100.0  
 
Table 8. SEX 
 Frequency Percent Valid Percent Cumulative Percent 
Valid 
Male 49 81.7 81.7 81.7 
Female 11 18.3 18.3 100.0 
Total 60 100.0 100.0  
 
Table 9. ALCOHOL 
 Frequency Percent Valid Percent Cumulative Percent 
Valid 
- 15 25.0 25.0 25.0 
+ 45 75.0 75.0 100.0 
Total 60 100.0 100.0  
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Table 10. VIRAL 
 Frequency Percent Valid Percent Cumulative Percent 
Valid 
- 54 90.0 90.0 90.0 
HBV 4 6.7 6.7 96.7 
HCV 2 3.3 3.3 100.0 
Total 60 100.0 100.0  
 
 
Table 11. OTHERS 
 Frequency Percent Valid Percent Cumulative Percent 
Valid 
- 50 83.3 83.3 83.3 
+ 10 16.7 16.7 100.0 
Total 60 100.0 100.0  
 
 
Table 12. JAUNDICE 
 Frequency Percent Valid Percent Cumulative Percent 
Valid 
- 3 5.0 5.0 5.0 
+ 57 95.0 95.0 100.0 
Total 60 100.0 100.0  
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Table 13. ASCITES 
 Frequency Percent Valid Percent Cumulative Percent 
Valid 
- 4 6.7 6.7 6.7 
+ 56 93.3 93.3 100.0 
Total 60 100.0 100.0  
 
 
Table 14. PORTAL HYPERTENSION 
 Frequency Percent Valid Percent Cumulative Percent 
Valid 
- 3 5.0 5.0 5.0 
+ 57 95.0 95.0 100.0 
Total 60 100.0 100.0  
 
 
Table 15. HEPATIC ENCEPHALOPATHY 
 Frequency Percent Valid Percent Cumulative Percent 
Valid 
- 50 83.3 83.3 83.3 
Gr1 7 11.7 11.7 95.0 
Gr2 3 5.0 5.0 100.0 
Total 60 100.0 100.0  
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Table 16. CHILD PUGH SCORING SYSTEM 
 Frequency Percent Valid Percent Cumulative Percent 
Valid 
A 5 8.3 8.3 8.3 
B 31 51.7 51.7 60.0 
C 24 40.0 40.0 100.0 
Total 60 100.0 100.0  
 
 
Table 17. QTc INTERVAL PROLONGATION IN SECONDS WITH 
NORMAL SERUM ELECTROLYTES 
 Frequency Percent Valid Percent Cumulative Percent 
Valid 
0.45 3 5.0 5.0 5.0 
0.46 6 10.0 10.0 15.0 
0.47 1 1.7 1.7 16.7 
0.48 5 8.3 8.3 25.0 
0.5 2 3.3 3.3 28.3 
0.55 3 5.0 5.0 33.3 
0.56 3 5.0 5.0 38.3 
NO 37 61.7 61.7 100.0 
Total 60 100.0 100.0  
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Table 18. LVDD GRADES 
Valid Frequency Percent Valid Percent Cumulative Percent 
Gr.1 LVDD 16 26.7 26.7 26.7 
Gr.2 LVDD 8 13.3 13.3 40.0 
NO LVDD 36 60.0 60.0 100.0 
Total 60 100.0 100.0  
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Table 19. LVDD 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 
NO 36 60.0 60.0 60.0 
LVDD 24 40.0 40.0 100.0 
Total 60 100.0 100.0  
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Table 20. CIRRHOTIC CARDIOMYOPATHY 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 
NO 37 61.7 61.7 61.7 
LVDD -+ QTc 
prolongation 23 38.3 38.3 100.0 
Total 60 100.0 100.0  
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  DISTRIBUTION PATTERNS OF DEMOGRAPHICAL, CLINICAL AND 
BIOCHEMICAL PARAMETERS IN CIRRHOTIC CARDIOMYOPATHY 
                             
 
                                     Table 21. AGE  DISTRIBUTION  
 
 Count Column N  % 
Age Group 
30-40Years 1 4.3% 
41-50 years 13 56.5% 
51-60 years 8 34.8% 
Above 60 Years 1 4.3% 
 
 
 
  
  
 
 Among 23 patients of cirrhotic cardiomyopathy, most cases (13 patients) 
occur in the age  group of 41-50 (57%) years. 
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                             Table22. SEX DISTRIBUTION 
  
 Count Column N  % 
Sex 
Male 19 82.6% 
Female 4 17.4% 
 
 
 
 
 
 
 
 
 Among 23 patients of cirrhotic cardiomyopathy, 19 patients (83%) were 
males and 4 patients (17%) were females. 
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Table 23. ETIOLOGICAL DISTRIBUTION PATTERNS 
 
 
a) ALCOHOL 
 
 Count Column N  % 
ALCOHOL 
- 6 26.1% 
+ 17 73.9% 
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b) VIRAL 
 
 Count Column N % 
VIRAL 
- 20 87.0% 
HBV 3 13.0% 
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c) OTHERS 
 
 Count Column N  % 
OTHERS 
- 19 82.6% 
+ 4 17.4% 
 
 
 
 
 
 
 
 In our study group, the most common cause for cirrhotic cardiomyopathy 
was alcohol seen in 17 patients (74%). 
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Table 24. DISTRIBUTION OF JAUNDICE AND ASCITES 
 
  Count Column N % 
JAUNDICE + 23 100.0% 
ASCITES + 23 100.0% 
 
 
 
 
 
 
 
 In our study group, all the 23 patients of cirrhotic cardiomyopathy (100%) 
were having jaundice and ascites. 
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Table 25. DISTRIBUTION OF PORTAL HYPERTENSION 
 
  Count Column N % 
PORTAL 
HYPERTENSION 
- 1 4.3% 
+ 22 95.7% 
   
 
 
 
 
 
 
 In our study group, portal hypertension was present in 22 patients of 
cirrhotic cardiomyopathy (96%). 
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Table 26. DISTRIBUTION PATTERN OF HEPATIC 
ENCEPHALOPATHY 
 
  Count Column N  % 
HEPATIC 
ENCEPHALOPATHY 
- 15 65.2% 
Gr1 5 21.7% 
Gr2 3 13.0% 
 
 
 
 
 
 
 In our study group, Grade 1 Hepatic Encephalopathy was present in 5 
patients (22%) and Grade 2 Hepatic Encephalopathy was present in 3 patients 
(13%) of cirrhotic cardiomyopathy. 
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Table 27. DISTRIBUTION PATTERN OF SERUM ALBUMIN LEVELS 
 
  Count Column N  % 
SERUM ALBUMIN 
ABNORMAL 21 91.3% 
NORMAL 2 8.7% 
 
 
 
 
 
 
 In our study group, 21 patients of cirrhotic cardiomyopathy (91.3%) were 
found to have  abnormal serum albumin levels.  
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Table 28. DISTRIBUTION PATTERN OF SERUM BILIRUBIN LEVELS 
 
  Count Column N  % 
SERUM BILLRUBIN 
<2 2 8.7% 
2.1-4 6 26.1% 
4.1-10 7 30.4% 
ABOVE 10 8 34.8% 
 
 
 
 
 
 In our study group, most patients of cirrhotic cardiomyopathy were found 
to have increased serum bilirubin levels above 10 (35%). 
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Table 29. CHILD PUGH SCORING SYSTEM FOR CIRRHOTIC 
CARDIOMYOPATHY CASES 
 
CHILDPUGH SCORING 
SYSTEM Count 
Column N 
% 
B 13 56.5% 
C 10 43.5% 
TOTAL 23 100.0% 
 
 
 
 
 
 
 
 In our study group, out of 23 patients of cirrhotic cardiomyopathy, 13 
patients were in class B (57%), 10 patients were in class C (43.5%). 
  
57%
43%
CHILD PUGH SCORING SYSTEM FOR 
CIRRHOTIC CARDIOMYOPATHY CASES
B
C
84 
 
Table 30. DISTRIBUTION PATTERNS OF DEMOGRAPHICAL, 
CLINICAL AND BIOCHEMICAL PARAMETERS IN CIRRHOTIC 
CARDIOMYOPATHY 
 
 Count Column N % 
AGE GROUP 
30-40Years 1 4.3% 
41-50 years 13 56.5% 
51-60 years 8 34.8% 
Above 60 Years 1 4.3% 
SEX 
Male 19 82.6% 
Female 4 17.4% 
ALCOHOL 
- 6 26.1% 
+ 17 73.9% 
VIRAL 
- 20 87.0% 
HBV 3 13.0% 
OTHERS 
- 19 82.6% 
+ 4 17.4% 
JAUNDICE + 23 100.0% 
ASCITES + 23 100.0% 
PORTAL_ 
HYPERTENSION 
- 1 4.3% 
+ 22 95.7% 
HEPATIC_ 
ENCEPHALOPATHY 
- 15 65.2% 
Gr1 5 21.7% 
Gr2 3 13.0% 
SERUM_ALBUMIN 
Abnormal 21 91.3% 
Normal 2 8.7% 
SERUM TOTAL 
BILIRUBIN 
<2 2 8.7% 
2.1-4 6 26.1% 
4.1-10 7 30.4% 
Above10 8 34.8% 
 
 
  
 
Discussion 
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DISCUSSION 
 
 Our study was conducted in patients with cirrhosis of liver to know 
the prevalence of cirrhotic cardiomyopathy in decompensated liver disease 
patients and to establish diastolic dysfunction as an early indicator of 
cirrhotic cardiomyopathy. Our study population included 60 patients who 
were diagnosed as cirrhosis of liver  by clinical, biochemical and 
radiological evidence. All 60 patients were evaluated for presence of   QTc 
prolongation in ECG and diastolic dysfunction by conventional 
echocardiography and hence were screened for the presence of cirrhotic 
cardiomyopathy. Analysis was made using Chi-Square test 
 
 to find the prevalence of cirrhotic cardiomyopathy and to study the 
correlation between demographical, etiological, clinical, biochemical 
parameters and diastolic dysfunction in decompensated liver diseased 
patients and their distribution patterns in cirrhotic cardiomyopathy.   
 to establish the correlation between severity of liver disease (child 
pugh scoring system) and diastolic dysfunction and hence to establish 
diastolic dysfunction as an early indicator in cirrhotic 
cardiomyopathy.  
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Following were the observations made from our study in cirrhotic patients.  
Age distribution:  
           Among 23 patients of cirrhotic cardiomyopathy, most cases (13 
patients) occur in the age  group of 41-50 (57%) years. This showed that 
cirrhotic cardiomyopathy  most commonly occurs in  adults.  
 
Sex distribution: 
 Among 23 patients of cirrhotic cardiomyopathy, 19 patients (83%) 
were males and 4 patients(17%) were females. Male to female ratio is 4.7:1.   
 
Etiological distribution: 
 In our study group, the most common cause for cirrhotic 
cardiomyopathy was alcohol seen in 17 patients (74%). 
 
Distribution patterns of Clinical and biochemical parameters: 
 Ma et al [39] study reported that in patients with jaundice, the 
increased concentration of bile salts lead to cardiac contractile dysfunction 
and Dadhich et al study [3] showed that 80% cirrhotic patients with ascites 
had Grade 1 &2 LVDD as compared to 60% without ascites. In our study 
group, all the 23 patients of cirrhotic cardiomyopathy (100%) were having 
jaundice and ascites.  
 
 Portal hypertension was present in 22 patients (96%), Grade 1 
Hepatic Encephalopathy was present in 5 patients (22%) and Grade 2 
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Hepatic Encephalopathy was present in 3 patients (13%) of cirrhotic 
cardiomyopathy.  
 
 Among 23 patients of cirrhotic cardiomyopathy, 21 patients (91.3%) 
were found to have  abnormal serum albumin levels and most patients were 
found to have increased serum bilirubin levels above 10 (35%). 
 
Child-Pugh class to correlate severity of diastolic dysfunction: 
 Our study showed LVDD in 24 /60 (40%) cirrhotic patients. This was 
almost similar to Ruiz del Arbol et al [2] study which showed LVDD in 
37/80 (46%).      
 
 In our study, out of 60 patients, 31 patients (52%) were in class B, 24 
patients (40%) were in class C and  5 patients (8%) were in class A. Out of 
23 patients of cirrhotic cardiomyopathy, 13 patients were in class B (57%), 
10 patients were in class C (43.5%). Majority of patients were in class B. 
Achecar and Gonzalec-Tallon [6] showed that diastolic dysfunction of left 
ventricle was exacerbated by liver disease. The result of the study was 
similar to our study which showed that severity of diastolic dysfunction  has 
highly significant correlation (p-value<0.001) with severity of liver disease 
as assessed by child pugh scoring system. Hence diastolic dysfunction 
serves as an early indicator in assessing the severity of liver disease in 
decompensated liver diseased patients.  
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 Torregrosa 1 et al [24] in a study showed significant improvement in 
cardiac contractile function between 6-12 months after liver transplantation. 
Child-Pugh class is a good indicator of the severity of liver disease. 
However, in patients with cirrhotic cardiomyopathy, cardiac 
decompensation sets in after invasive procedures. Hence patients belonging 
to child pugh class B&C can be subjected to echocardiographic evaluation 
for the presence of diastolic dysfunction. This helps to identify the patients 
at risk earlier before undergoing liver transplantation which could be 
beneficial in improving the overall survival outcome rates. 
 
  
Conclusion 
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CONCLUSION 
 
Following results were concluded from our study:  
 Cirrhotic Cardiomyopathy is prevalent in two-fifth of cirrhotic 
patients. 
 About 40% of patients under study had QTc prolongation and 
diastolic dysfunction. These parameters form the basic tools for the 
diagnosis of Cirrhotic Cardiomyopathy in patients with liver 
Cirrhosis. 
 Patients with Cirrhotic Cardiomyopathy have normal systolic 
function at rest. 
 Cirrhotic Cardiomyopathy is clinically and pathophysiologically 
different from alcoholic heart muscle disease. 
 Cirrhotic Cardiomyopathy is independent of age, sex and etiological 
factors. 
 Diastolic dysfunction of varying severity was seen in hundred 
percentage of Cirrhotic Cardiomyopathy patients with jaundice and 
ascites as compared to patients without jaundice and ascites. 
 Increasing severity of diastolic dysfunction has significant correlation 
with increasing serum bilirubin levels and increasing severity of 
hepatic encephalopathy. 
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 Increasing severity of liver cirrhosis from Child pugh class A to C has 
highly significant correlation with increasing severity of diastolic 
dysfunction, hence “Diastolic Dysfunction serves as an early 
indicator of Cirrhotic Cardiomyopathy in assessing the severity 
in Decompensated Liver diseased patients”. 
 Treatment is non-specific. Liver transplantation may revert the 
cardiac dysfunction but surgery and TIPS aggravate the same in 
Cirrhotic Cardiomyopathy. 
  Patients belonging to Child Pugh Class B and C can be subjected to 
Echocardiographic evaluation for the presence of diastolic 
dysfunction which is beneficial  in improving the survival outcomes 
in  patients undergoing liver transplantation. 
 
  
Limitations of the study 
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LIMITATIONS OF THE STUDY 
 
 The study size is small and hence necessitates the need of a larger study 
with wide range of study population. 
 Silent ischemia cannot be ruled out by Coronary angiogram. 
 Congenital long QT syndrome cannot be ruled out. 
 E/A ratio in grading LVDD by conventional echocardiography has 
several limitations as it is strongly dependent on preload and also 
requires age correction. Hence the most accurate modality in assessing 
the LVDD is by pulsed Tissue Doppler Imaging which is independent of 
volume status and left atrial pressure. 
 Patients were not subjected to surgical / physiological / pharmacological 
stress challenges. 
 The role of molecular biomarkers of diastolic dysfunction such as BNP 
was not analysed. 
 Genetic predisposition to Cirrhotic Cardiomyopathy was not studied. 
 The fact whether Cirrhotic Cardiomyopathy affects mortality cannot be 
assessed due to lack of clinical follow-up of patients. 
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1 44 M + - - + + + - 22 4.5 11.6 120 16.5/1.3 B DCLD/ASCITES DCLD/ASCITES/PHTN NO Gr.1 LVDD 
2 52 M  + - - + + + - 2.4 2.2 10 138 15/1.4 B DCLD/ASCITES DCLD/ASCITES/PHTN NO NO LVDD 
3 48 M  + - - + + + - 17.7 2.6 5.2 69 22/1.7 C DCLD/ASCITES DCLD/ASCITES/PHTN NO NO LVDD 
4 70 M - HBV - + + + - 24.5 2.5 9.7 178 14.7/1.18 C DCLD/ASCITES DCLD/ASCITES NO NO LVDD 
5 50 M - - + + + + - 5.2 3.0 9 80 24/1.85 C DCLD/ASCITES/ 
SPLENOMEGALY 
DCLD/ASCITES/PHTN 0.55  Gr.2 LVDD 
6 56 M + - - + + + - 9.5 2.0 7.7 59 20/1.56 C DCLD/ASCITES 
SPLENOMEGALY 
DCLD/ASCITES/PORTAL 
CAVERNOMA 
0.56 Gr.2 LVDD 
7 44 M + - - + + + - 21.5 2.5 9.4 101 16/1.20 C DCLD/ASCITES DCLD/ASCITES NO NO LVDD 
8 41 M + - - + + + - 3.2 2.5 8 133 14/1.28 C DCLD/ASCITES DCLD/ASCITES NO NO LVDD 
9 52 M + - - + + + - 1.0 2.8 8.9 160 15.5/1.3 B DCLD/ASCITES DCLD/ASCITES NO NO LVDD 
10 39 M + - - + + + - 6.9 2.1 9.1 115 28/2.17 C DCLD/ASCITES DCLD/ASCITES/PHTN NO NO LVDD 
11 54 M + - - + + + Gr
2 
12.4 2.6 5.9 85 31/2.36 C DCLD/ASCITES DCLD/ASCITES/PHTN/ 
Gr 2 VARICES 
0.48 Gr.1 LVDD 
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12 56 M + - - + + + Gr
1 
2.2 3 5.6 93 15/1.01 B DCLD/ASCITES DCLD/ASCITES/PHTN 0.48 Gr.1 LVDD 
13 42 M + - - + + + Gr
1 
5.0 2.0 10.9 155 15/1.23 C DCLD/ASCITES DCLD/ASCITES/PHTN 0.5 Gr.2 LVDD 
14 48 M + - - + + + Gr
1 
22 2.7 10.9 126 16/1.47 C DCLD/ASCITES DCLD/ASCITES/PHTN 0.46 Gr.1 LVDD 
15 47 F - - + + + + - 0.2 2.0 10.1 262 16/1.47 B DCLD/ASCITES DCLD/ASCITES/PHTN 0.48 Gr.1 LVDD 
16 65 F + - - + + + - 1.3 2.8 10.1 66 14/1.11 B DCLD/ MILD 
SPLENOMEGALY/ 
? HCC 
DCLD/ASCITES/PHTN/ 
Gr.1 VARICES 
NO NO LVDD 
17 80 M + - - + + - - 2.9 3.0 10.3 34 15/1.28 B DCLD/? HCC DCLD/ASCITES/?HCC 0.55 Gr.1 LVDD 
18 44 M + - - + + - - 0.8 3.0 5.2 279 14/1.33 A DCLD/HSM DCLD NO NO LVDD 
19 41 M + - - + + + - 3.5 2.2 11.5 47 13/1.12 C DCLD/ASCITES 
SPLENOMEGALY 
DCLD/ASCITES NO NO LVDD 
20 49 M + - - + + + - 0.9 2.9 12.8 139 12.9/1.2 B DCLD/ASCITES/ 
MILD 
SPLENOMEGALY 
DCLD/ASCITES/PHTN NO NO LVDD 
21 35 M + - - - - - - 1.5 3.4 10.3 80 16 /1.60 A DCLD/MILD 
SPLENOMEGALY 
DCLD/PHTN NO NO LVDD 
22 36 F - - + + + + - 7.1 2.9 5.8 61 15/1.48 B DCLD/ASCITES 
/MASSIVE 
SPLENOMEGALY 
NCPF/DCLD/ 
ASCITES/ 
PHTN 
NO NO LVDD 
23 58 M + - - + + + Gr 
1 
11.2 1.7 9.5 255 14.6/1.32 C DCLD/ASCITES DCLD/ASCITES/PHTN NO NO LVDD 
24 42 M + - - + + + - 1.7 2.1 7.7 58 15.3/1.26 B DCLD/MASSIVE 
ASCITES 
DCLD/ASCITES/PHTN NO NO LVDD 
25 50 F - - + + + + - 0.7 3.1 9.0 35 14.39/1.2 B DCLD/ASCITES/ 
MASSIVE 
SPLENOMEGALY/ 
Rt.PLEURAL 
EFFUSION 
DCLD/ASCITES/PHTN/ 
DILATED VEINS 
NO NO LVDD 
26 53 F - HCV - + + + - 0.6 2.1 7.7 91 15.1/1.3 B DCLD/ASCITES DCLD/ASCITES/PHTN NO NO LVDD 
27 60 M + - - + + + Gr 
1 
9.6 2.8 9.6 38 14.7/1.23 B DCLD/ASCITES/ 
SPLENOMEGALY 
DCLD/ASCITES/PHTN/ 
Gr.2 VARICES 
0.45 Gr.1 LVDD 
28 48 M - HBV - + + + - 3.9 4.1 6.2 153 13.4/1.17 B DCLD/ASCITES/ 
? HCC 
DCLD/ASCITES/? HCC 0.46 Gr.1 LVDD 
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29 40 M + - - + + + - 3.2 3.3 10 87 18.7/1.6 B DCLD/ASCITES/ 
SPLENOMEGALY 
DCLD/ASCITES/PHTN 0.45 Gr.1 LVDD 
30 48 M + - - + + + - 2.5 2.5 9.8 96 17.8/1.7 C DCLD/ASCITES/ 
SPLENOMEGALY 
DCLD/ASCITES/PHTN NO NO LVDD 
31 45 M + - - + + + - 1.8 3.0 10.2 112 12.9/1.0 B DCLD/ASCITES DCLD/ASCITES NO NO LVDD 
32 51 M + - - + + + - 4.8 2.8 8.6 106 14.3/1.2 B DCLD/ASCITES DCLD/ASCITES NO NO LVDD 
33 55 M + - - + + + - 7.0 2.0 9.4 91 16.4/1.7 C DCLD/ASCITES DCLD/ASCITES/PHTN NO NO LVDD 
34 46 F - - + + + + - 1.9 3.1 7.4 68 14.3/0.9 B DCLD/ASCITES DCLD/ASCITES 0.46 Gr 1 LVDD 
35 52 F - - + + - + - 1.6 2.8 6.5 56 15.3/1.4 A DCLD/ MILD 
SPLENOMEGALY 
DCLD/PHTN NO NO LVDD 
36 55 M + - - + + + - 3.4 2.7 8.9 142 12.1/1.03 C DCLD/ASCITES DCLD/ASCITES NO NO LVDD 
37 43 M + - - + + + - 8.7 2.8 10.5 113 13.0/1.3 B DCLD/ASCITES DCLD/ASCITES/PHTN 0.46 Gr 1 LVDD 
38 53 M + HBV - + + + - 12 2.2 6.8 92 19.6/2.0 C DCLD/ASCITES DCLD/ASCITES/PHTN/ 
Gr.2 VARICES 
0.5 Gr 2 LVDD 
39 40 M + - - + + + - 6.4 3.4 10.2 156 13.1/1.25 B DCLD/ASCITES DCLD/ASCITES/PHTN NO NO LVDD 
40 45 F + - - + + + Gr 
1 
10.3 1.9 4.6 63 14.9/1.6 C DCLD/ASCITES/ 
? HCC 
DCLD/ASCITES/? HCC 0.47 Gr 1 LVDD 
41 58 M + - - + + + - 9.4 2.6 10.6 143 16.3/1.7 C DCLD/ASCITES DCLD/ASCITES/PHTN NO NO LVDD 
42 50 F - - + + + + - 5.6 3.1 7.2 84 15.71/1.4 B DCLD/ASCITES DCLD/ASCITES 0.45 Gr 1 LVDD 
43 57 M + - - + + + - 3.7 2.9 11.2 159 17.6/1.5 B DCLD/ASCITES DCLD/ASCITES/PHTN 0.46 Gr 1 LVDD 
44 48 M + - - + + + Gr 
2 
17.3 1.8 7.5 54 20/ 2.17 C DCLD/ASCITES DCLD/ASCITES/PHTN 0.56 Gr 2 LVDD 
45 56 M + - - + + + Gr 
1 
14.3 2.5 6.2 68 18.3/1.9 C DCLD/ASCITES/ 
SPLENOMEGALY 
DCLD/ASCITES/PHTN/ 
DILATED VEINS 
0.55 Gr 2 LVDD 
46 60 F - - + + + + - 3.9 2.9 7.0 116 14.2/1.2 B DCLD/ASCITES DCLD/ASCITES/PHTN NO NO LVDD 
47 43 M - - + - - + - 0.8 3.3 9.8 140 12.08/1.1 A DCLD DCLD/Gr.2 VARICES NO NO LVDD 
48 55 M + - - + + + - 1.4 2.7 12 201 14.12/1.4 B DCLD/ASCITES DCLD/ASCITES/PHTN NO NO LVDD 
49 49 M - HCV - + + + - 1.9 3.0 7.5 95 13.6/1.3 B DCLD/ASCITES/ 
? HCC 
DCLD/ASCITES/PHTN/ 
? HCC 
NO NO LVDD 
50 45 M + - - + + + - 10.3 2.3 6.4 78 15.8/1.5 C DCLD/ASCITES DCLD/ASCITES/PHTN 0.48 Gr 2 LVDD 
DIASTOLIC DYSFUNCTION AS AN EARLY INDICATOR OF CIRRHOTIC CARDIOMYOPATHY IN 
DECOMPENSATED LIVER DISEASE 
 
MASTER CHART 
                                                                                    
51 50 M + - - + + + - 2.4 2.6 13.2 196 19.1/1.8 C DCLD/ASCITES DCLD/ASCITES/PHTN NO NO LVDD 
52 45 M - - + + + + - 2.7 3.2 9.2 98 15/1.16 B DCLD/ASCITES/ 
MASSIVE 
SPLENOMEGALY 
DCLD/PHTN/  
Gr.3 VARICES 
NO NO LVDD 
53 48 M + - - - + + - 1.0 3.1 10.2 123 12.8/1.07 B DCLD/ASCITES DCLD/ASCITES/PHTN NO NO LVDD 
54 54 M + - - + + + - 2.5 2.9 9.4 89 14.7/1.3 B DCLD/ASCITES DCLD/ASCITES/PHTN NO NO LVDD 
55 60 M + - - + - + - 1.4 3.2 8.9 114 13.3/1.3 A DCLD/ASCITES/ 
SPLENOMEGALY 
DCLD/PHTN NO NO LVDD 
56 56 F - HBV - + + + Gr 
2 
13.4 2.0 6.5 85 24.6/2.0 C DCLD/ASCITES DCLD/ASCITES/PHTN 0.56 Gr 2 LVDD 
57 45 M + - - + + + - 4.0 3.2 7.2 96 17.9/1.4 B DCLD/ASCITES DCLD/ASCITES/PHTN 0.46 Gr 1 LVDD 
58 47 M + - - + + + - 9.6 2.9 5.5 75 18.8/1.6 B DCLD/ASCITES DCLD/ASCITES/PHTN 0.48 Gr 1 LVDD 
59 48 M + - - + + + - 6.3 2.4 11.9 123 14.4/1.2 C DCLD/ASCITES/ 
SPLENOMEGALY 
DCLD/ASCITES/PHTN/ 
DILATED VEINS 
NO NO LVDD 
60 40 M + - - + + + - 3.1 2.8 9.6 234 16.5/1.56 B DCLD/ASCITES DCLD/ASCITES/PHTN NO NO LVDD 
 
DCLD-decompensated liver disease, PHTN-portal hypertension, LVSF-left ventricular systolic function,  
LVDD-left ventricular diastolic dysfunction, Gr.-grade, QTc-rate corrected QT, HCC-hepatocellular carcinoma,  
HSM-hepatosplenomegaly, NCPF-noncirrhotic portal fibrosis. 
Annexure 
ABBREVIATIONS 
 
aPTT - activated Partial Tissue Thromboplastin time 
ACE - Angiotensin converting enzyme 
ALT - Alanine aminotransferase 
AST - Aspartate aminotransferase 
AT II - Angiotensin  II 
AV - Arteriovenous 
BT - Bleeding time 
BNP - Brain natriuretic peptide 
CT - Clotting time 
CPC - Child Turcotte Pugh classification 
CT - Computed tomography 
DCLD - Decompensated liver disease 
ECG - Electrocardiogram 
ET - Endothelin 
FEV1 - Forced Expiratory Volume in one second 
FVC - Forced Vital Capacity 
GGT - Gammaglutamyl transpeptidase 
GI - Gastrointestinal 
HBV - Hepatitis B virus 
HCV - Hepatitis C virus 
HE - Hepatic encephalopathy 
HPS - Hepato Pulmonary Syndrome 
HRS - Hepatorenal syndrome 
HR - Heart Rate 
INR - International normalized ratio 
LA - Left atrium 
LV - Left ventricle 
LVDD - Left ventricular diastolic dysfunction 
  
LVEF - Left ventricular ejection function 
LVSF - Left ventricular systolic function 
L-NAME - NG-nitro-L arginine methyl ester 
LFT - Liver function test 
MELD - Model for End stage Liver Disease 
NA - Noradrenaline 
NO - Nitric oxide 
OLT - Orthotopic liver transplantation 
PaO2 - Partial pressure of oxygen 
PCWP - Pulmonary Capillary Wedge Pressure 
PAH - Pulmonary artery hypertension 
PEFT - Peak expiratory flow rate 
PFT - Pulmonary function test 
PPH - Porto Pulmonary hypertension 
PT - Prothrombin time 
RFT - Renal function test 
SBP - Spontaneous bacterial peritonitis 
SGOT - Serum glutamic oxaloacetic transaminase 
SGPT - Serum glutamic pyruvic transaminase 
SVR - Systemic vascular resistance 
SNS - Sympathetic nervous system 
TIPS - Transjugular intrahepatic portosystemic shunt 
 
 
  
PROFORMA 
 
“DIASTOLIC DYSFUNCTION AS AN EARLY INDICATOR OF CIRRHOTIC 
CARDIOMYOPATHY IN DECOMPENSATED LIVER DISEASE” 
NAME: 
ADDRESS: 
AGE/SEX: 
OCCUPATION: 
I.P./O.P. NO.: 
SOCIOECONOMIC STATUS:   
PRESENTING COMPLAINTS: 
 Abdominal distension  
 Abdominal pain 
 Yellowish discolouration of eyes/urine 
 Vomiting/loose stools 
 Swelling of legs  
 Breathlessness  
 Fever/Cough with expectoration  
 Hematemesis/malena/hematuria /other bleeding manifestations 
 Easy fatiguability  
 Loss of appetite/weight 
 Altered sleep pattern 
 Others  
 
PAST HISTORY: 
 Previous similar episodes 
 Jaundice   
 Tattooing/drug intake 
 Blood transfusion/surgery 
 Vaccination 
 Ischemic heart disease 
  
 Hypertension 
 Diabetes  
 Pulmonary TB  
 Bronchial asthma  
 Thyroid disorders 
 STD exposure 
 Other chronic ailments/terminal illness 
 
PERSONAL HISTORY:  
 Smoking  
 Alcohol   
 Diet  
 
FAMILY HISTORY: 
TREATMENT HISTORY: 
GENERAL EXAMINATION: 
  Conscious 
  Co-operative 
  Built      
  Nourishment   
  Febrile/afebrile 
  Height  
  Weight   
  Pallor  
  Icterus   
  Clubbing  
  Cyanosis   
  Pedal edema  
  Significant Lymphadenopathy  
  Jugular venous pulse  
  Signs of Liver cell failure 
  Markers of TB 
  Markers of HIV   
 
VITAL SIGNS:   
 Pulse rate 
 Blood pressure 
 Respiratory rate 
 Temperature 
 SPO2 
 
SYSTEMIC EXAMINATION:   
 PER ABDOMEN:   
 CARDIOVASCULAR SYSTEM:   
 RESPIRATORY SYSTEM:   
 CENTRAL NERVOUS SYSTEM:   
 
INVESTGATIONS: 
 Liver function tests-Total bilirubin 
                                 Direct/Indirect bilirubin 
                                 SGOT/SGPT 
                                 Serum total protein/albumin 
                                 Albumin:Globulin ratio 
                                 PT-INR,aPTT 
                                 BT/CT 
 Complete hemogram 
 Renal function tests&serum electrolytes 
 Viral markers 
 USG Abdomen&pelvis 
 Portal venous Doppler study 
 12-lead ECG  
 ECHOCARDIOGRAPHY 
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 INFORMATION SHEET 
 
 We are conducting a study on “DIASTOLIC DYSFUNCTION    AS AN 
EARLY INDICATOR OF CIRRHOTIC CARDIOMYOPATHY IN 
DECOMPENSATED LIVER DISEASE.” among patients attending Rajiv 
Gandhi Government General Hospital, Chennai and for that your co-operation to 
undergo relevant investigations as per need may be valuable to us. 
 
 The purpose of this study is to find the occurrence of diastolic dysfunction 
as an early indicator of cirrhotic cardiomyopathy in decompensated liver diseased 
patients. 
 
We are selecting certain cases and if you are found eligible, we would like to 
perform extra tests and you will be subjected to a non invasive procedure like 
echocardiography which in any way do not affect your final report or 
management. 
The privacy of the patients in the research will be maintained throughout the 
study. In the event of any publication or presentation resulting from the research, 
no personally identifiable information will be shared. 
Taking part in this study is voluntary. You are free to decide whether to 
participate in this study or to withdraw at any time; your decision will not result in 
any loss of benefits to which you are otherwise entitled. 
The results of the special study may be intimated to you at the end of the study 
period or during the study if anything is found abnormal which may aid in the 
management or treatment. 
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